Unknown

Dataset Information

0

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo.


ABSTRACT: Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP-ribosylhydrolase activity and a possible drug target. To determine the therapeutic potential of Mac1 inhibition, we generated recombinant viruses and replicons encoding a catalytically inactive NSP3 Mac1 domain by mutating a critical asparagine in the active site. While substitution to alanine (N40A) reduced catalytic activity by ~10-fold, mutations to aspartic acid (N40D) reduced activity by ~100-fold relative to wildtype. Importantly, the N40A mutation rendered Mac1 unstable in vitro and lowered expression levels in bacterial and mammalian cells. When incorporated into SARS-CoV-2 molecular clones, the N40D mutant only modestly affected viral fitness in immortalized cell lines, but reduced viral replication in human airway organoids by 10-fold. In mice, N40D replicated at >1000-fold lower levels compared to the wildtype virus while inducing a robust interferon response; all animals infected with the mutant virus survived infection and showed no signs of lung pathology. Our data validate the SARS-CoV-2 NSP3 Mac1 domain as a critical viral pathogenesis factor and a promising target to develop antivirals.

SUBMITTER: Taha TY 

PROVIDER: S-EPMC10153184 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis <i>in vivo</i>.

Taha Taha Y TY   Suryawanshi Rahul K RK   Chen Irene P IP   Correy Galen J GJ   O'Leary Patrick C PC   Jogalekar Manasi P MP   McCavitt-Malvido Maria M   Diolaiti Morgan E ME   Kimmerly Gabriella R GR   Tsou Chia-Lin CL   Martinez-Sobrido Luis L   Krogan Nevan J NJ   Ashworth Alan A   Fraser James S JS   Ott Melanie M  

bioRxiv : the preprint server for biology 20230510


Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP-ribosylhydrolase activity and a possible drug target. To determine the therapeutic potential of Mac1 inhibition, we generated recombinant viruses and replicons encoding a catalytically inactive NSP3 Mac1 domain by mutating a critical asparagine in the active site. While substitution to alanine (N40A) reduced catalytic activity by ~10-fo  ...[more]

Similar Datasets

| S-EPMC10499221 | biostudies-literature
| S-EPMC7684785 | biostudies-literature
| S-EPMC7341687 | biostudies-literature
| S-EPMC3219718 | biostudies-literature
| S-EPMC8769010 | biostudies-literature
| S-EPMC7431798 | biostudies-literature
| S-EPMC6069204 | biostudies-literature
| S-EPMC7111695 | biostudies-literature
| S-EPMC10747130 | biostudies-literature
| S-EPMC10793406 | biostudies-literature